Zoetis (ZTS) Tops Q3 EPS by 10c; Issues Solid Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Zoetis (ZTS) PT Lifted to $58 at Piper Jaffray on Solid Q3 and Ahead of Simparica Approval
November 4, 2015 8:52 AM ESTPiper Jaffray analyst Kevin Ellich reiterated an Overweight rating and boosted his price target on Zoetis Inc. (NYSE: ZTS) to $58.00 (from $55.00) following solid Q3 results. The analyst sees Simparica approval coming soon.
Ellich commented, "ZTS' Q3 results were impressive as the company... More
Zoetis (ZTS) Announces 3Q Beat and Raise Along with PHARMAQ Deal; Guggenheim Reiterates Buy
November 3, 2015 1:17 PM ESTGuggenheim reiterated a Buy rating and $60.00 price target on Zoetis Inc. (NYSE: ZTS) following the company's 3Q15 earnings results. ZTS reported 3Q15 EPS of $0.50, $0.10 higher than consensus, and then increased its '15 and '16 EPS guidance to $1.70-$1.74 from $1.63-$1.68 and $1.84-$1.94 from $1.81-$1.93, respectively. The release also included the announcement of a deal with PHARMAQ. Management stated that PHARMAQ... More
